Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Massimo Andreoni and Massimo Puoti.
Massimo Andreoni
Connection Strength
0.650
Massimo Puoti
  1. Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients. PLoS One. 2018; 13(2):e0192627.
    View in: PubMed
    Score: 0.189
  2. Current and future challenges in HCV: insights from an Italian experts panel. Infection. 2018 Apr; 46(2):147-163.
    View in: PubMed
    Score: 0.185
  3. Real life experiences in HCV management in 2018. Expert Rev Anti Infect Ther. 2019 02; 17(2):117-128.
    View in: PubMed
    Score: 0.050
  4. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. Sci Rep. 2018 06 12; 8(1):8988.
    View in: PubMed
    Score: 0.048
  5. Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. PLoS One. 2017; 12(5):e0177352.
    View in: PubMed
    Score: 0.045
  6. Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. PLoS One. 2017; 12(5):e0177402.
    View in: PubMed
    Score: 0.045
  7. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016. New Microbiol. 2017 Apr; 40(2):86-98.
    View in: PubMed
    Score: 0.044
  8. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017 04; 37(4):514-528.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.